The drive back from Cape Cod took three hours and eleven minutes, and Claire spent most of it on the phone.
Sarah had the emergency motion pulled and annotated by the time they crossed the Sagamore. Ethan drove while Claire read aloud, her voice flat and legal. Helix wasn't just asking Judge Okafor to enjoin the study. They were asking for a temporary restraining order on the publication of the protocol itself, arguing that the registry entry constituted disclosure of trade secrets.
"They filed at 11:40 last night," Claire said. "Two hours after we posted."
"Somebody's watching the registry."
"Somebody has a Google Alert set to 'gender-stratified cardiac algorithm.'" She scrolled. "Their lead counsel is Deirdre Mott. She's good. She's the one who kept the Vioxx remand alive for eighteen months."
Ethan changed lanes. "Monday at eight gives us the weekend."
"Gives us sixty-eight hours." Claire looked out the window at the grey water of the bay. "We need two things by then. One, a response brief. Two, an answer to the question nobody's asking."
"Which is?"
"Why does Helix care?" She turned to him. "If the training data were genuinely stolen, they'd have filed a police report. They didn't. They filed a civil motion the same week we announced a prospective validation. That's not a theft claim. That's a suppression claim."
Ethan was quiet for a mile. "You think they're covering for the algorithm."
"I think they're covering for the algorithm's failure rate in women. And I think we should stop calling it a gender-variable algorithm and start calling it what it is." She typed a note into her phone. "A device that misses heart attacks in women at twice the rate it misses them in men."
They reached Boston at 4:40. The Bramble Center's office was a sublet on the fourth floor of a building near the Longwood Medical Area—two rooms, a shared kitchenette, and a conference table that had been a ping-pong table in its previous life. Maria was already there. So was Sarah, and so was a woman Claire had never met, sitting with her back very straight in a chair by the window.
"Dr. Claire Bennett," Sarah said. "This is Priya Raman. Deputy director of the Office of Cardiovascular Devices."
Claire's hand went cold around her bag. She set it down slowly.
"Dr. Raman," she said. "We weren't expecting you."
"I know." Raman was in her fifties, in a navy blazer, with reading glasses pushed up into her hair. "I flew in this morning. I asked Sarah to keep it quiet because I didn't want it turning into a hearing before it was a conversation."
Ethan came in behind Claire and stopped. Raman looked at him. "Dr. Cole. You wrote the registry entry."
"I did."
"It's the clearest piece of writing that's crossed my desk in a year." She gestured at the table. "Sit. Both of you."
They sat. Maria sat too, and flipped open a laptop, and said, "Recording, per our charter. Dr. Raman has given verbal consent."
"Thank you." Raman folded her hands. "I'll be direct, because I have a seven-forty flight back. The agency has been following your work since the Silverman letter went public. We've also been following Helix's. There's an internal working group that's been meeting on the CardiaSense question since November, and the conversation in that room has shifted."
"Shifted how?" Claire asked.
"From 'is there a problem' to 'what do we do about the problem.'" Raman took out a manila folder and slid it across the ping-pong table. "Nothing in this is public. I'm trusting you with it because I've read your protocol and it's the only one in the pipeline that would actually answer the question. But I need you to hear the trade."
Claire opened the folder. Tables. Coverage rates by sex. Confidence intervals that made her stomach drop.
"If you can demonstrate the sex-stratified algorithm outperforms the current device," Raman said, "the agency has a pathway to expedited review. Not approval—review. But there's appetite for it. This is a fatal miss in a top-five indication. The commissioner wants a solution inside a fiscal year."
Claire looked up. "That's not possible."
"I'm aware."
"No—I mean it's not possible *correctly*." She closed the folder. "Dr. Raman, our validation is prospective, randomized, and has a hard stopping rule. If the stratified arm underperforms, we stop and publish the failure. That take time. Eighteen months minimum. If you fast-track nationwide deployment on the strength of our data—"
"Fast-track is your word."
"—you'd be rolling out a retrained model to every hospital in the country on the strength of however many patients we can enroll before someone at the commissioner's office gets impatient."
Ethan's chair creaked as he leaned back. He wasn't looking at Claire or at Raman. He was looking at the folder.
"Dr. Raman," he said. "How many sites is the current device in?"
"Four hundred and forty-one."
"And how many of those sites report sex-stratified outcomes?"
Raman was silent.
"Then here's my question," Ethan said. "If the agency fast-tracks our algorithm nationwide, whose patients get enrolled?" He tapped the folder. "Because I've read the same coverage tables you have. The hospitals that report outcomes are the academic centers. The ones that don't are community hospitals in places like Roswell and Las Cruces and Poughkeepsie. Which means a fast rollout teaches us about wealthy white women in Boston and tells us nothing about the people the device is killing now."
Claire looked over at him. He had one hand flat on the table, and he was not blinking.
Raman studied Ethan for a long moment. "You're arguing against your own study."
"No. I'm arguing about the order of operations." He turned the folder around and slid it back toward her. "Run the validation. Then run a second one. Parallel. Same protocol, different sites—rural, safety-net, non-English. Fund it as one study, not two. If you have fiscal-year pressure, tell the commissioner the fiscal year is the reason you need more sites, not fewer."
"Funding for a second cohort doesn't exist."
"It exists," Claire said quietly. "It exists if the Foundation hears that the FDA asked for it."
Sarah had stopped typing. Maria had stopped typing. Even the building seemed to have stopped.
Raman's mouth did something that wasn't quite a smile. "You're asking me to put in writing that the agency requested broader enrollment."
"I'm asking you to put in writing what you already know," Claire said. "That a breakthrough that only works in Framingham isn't a breakthrough. It's a marketing claim."
The clock on the wall said 5:52. Raman closed her folder and stood.
"I can't promise you anything," she said. "I can tell you that I'll be in the room when the working group meets Monday. I can tell you what the fast-track memo is already drafted to say, and it doesn't say 'phased rollout.' It says 'accelerated national deployment.'"
"That would be a mistake."
"That would be a mistake," Raman agreed. "Come to Washington. Thursday. The working group takes outside testimony at ten o'clock. You'll have twenty minutes, and there will be a device-industry representative in the room with the same twenty minutes."
"Who?" Claire asked.
"You can guess." Raman picked up her coat. "Dr. Bennett. Dr. Cole. One more thing. The injunction on Monday—Helix's counsel has requested that the agency be named as an interested party. We declined. But we declined quietly, and we won't decline quietly forever. Whatever you do in that courtroom, understand that it's being read."
She left.
Maria closed the laptop. "Well," she said. "That's on the record."
Claire stood at the window and watched Raman's car pull out onto Longwood. Behind her, Ethan hadn't moved. She could feel him the way you feel a change in barometric pressure.
"Say it," she said.
"You didn't hedge." His voice was low. "She handed you a fast track and you told her it wasn't good enough."
"It isn't good enough."
"I know." He came to stand beside her. "That's not what I'm saying."
She turned. He was closer than she expected. The office had gone dark except for the desk lamp Maria had left on, and the streetlights were coming up along the avenue.
"There are going to be days," he said, "when you wonder whether you should have taken the deal. Whether you traded the whole rollout for a second cohort. Whether the version of me that sits on the DMC is going to cost you your career. I need you to know that I'd tell you to take the deal if I thought it would save one more woman."
"I know."
"Do you?"
"Yes." She reached up and straightened the collar of his shirt, which the drive had rumpled. "Ethan. Monday at eight, and then Thursday at ten. Two hearings in one week. If we win the injunction and lose Washington, none of it matters. If we win Washington and lose the injunction, none of it starts."
"So we need both."
"We need both." She picked up her bag and the folder. "Which means I have something to tell you before Monday. Something I should have told you last weekend."
He waited.
And in the doorway, Sarah said, "Claire—" and stopped. She was holding her phone out, screen up.
"Priya Raman just forwarded this," Sarah said. "It's the fast-track memo. The commissioner's office has already circulated a draft implementation model. It doesn't name our study."
Claire took the phone. Under the header, a table of go-live dates, by region, beginning in eleven weeks.
"It names our data," Sarah said. "It just doesn't name us."